首页> 外文OA文献 >Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases
【2h】

Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases

机译:软组织透明细胞肉瘤(恶性黑色素瘤):52例临床病理研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clear cell sarcomas are aggressive, rare soft tissue tumors and their classification among melanoma or sarcoma is still undetermined due to their clinical, pathologic, and molecular properties found in both types of tumors. This is a retrospective study of 52 patients with CCS seen between April 1979 and April 2005 in two institutions. The EWS-ATF-1 fusion transcript was studied in 31 patients and an activating mutation of the BRAF or NRAS gene was researched in 22 patients. 30 men and 22 women, with a mean age of 33 were studied. Forty-three tumors (82.69%) were located in the extremities, specially the foot (19 tumors). Median initial tumor size was 4.8 cm (1 to 15 cm). Necrosis involving more than 50% of the tumor cells was found in 14 cases (26.92%). High mitotic rate (>10) was found in 25 cases (48.07%). The EWS/ATF-1 translocation was found in 28 (53.84%) of 31 patients studied, and mutation of BRAF or NRAS was found in only 2 of 22 patients analyzed cases (3.84%). Among the tumor-associated parameters, only tumor size (>4 cm) emerged as a significant prognostic factor. Forty-nine patients had a localized disease at diagnosis (94.23%) and underwent surgical resection immediately (90%) or after neoadjuvant chemotherapy (CT) (10%). Various CT regimens were used in 37 patients (71.15%) with no significant efficacy. The 5- and 10-year OS rates were 59% and 41%, respectively. Tumor size was the only emerging prognosis factor in our series. Complete surgical resection remains the optimal treatment for this aggressive chemoresistant tumor.
机译:透明细胞肉瘤是侵袭性的,罕见的软组织肿瘤,由于在两种类型的肿瘤中都有其临床,病理学和分子特性,因此尚不清楚其在黑素瘤或肉瘤中的分类。这项回顾性研究在1979年4月至2005年4月期间在两个机构中对52例CCS患者进行了回顾。在31例患者中研究了EWS-ATF-1融合转录本,在22例患者中研究了BRAF或NRAS基因的激活突变。研究了30名男性和22名女性,平均年龄为33岁。四肢有43个肿瘤(占82.69%),尤其是足部(有19个肿瘤)。中位初始肿瘤大小为4.8厘米(1至15厘米)。 14例(26.92%)发现坏死占肿瘤细胞的50%以上。 25例中有丝分裂率高(> 10)(48.07%)。在研究的31例患者中有28例(53.84%)发现了EWS / ATF-1易位,在分析的22例患者中只有2例(3.84%)发现了BRAF或NRAS突变。在与肿瘤相关的参数中,只有肿瘤大小(> 4 cm)才是重要的预后因素。四十九名患者在诊断时患有局部疾病(94.23%),并立即接受手术切除(90%)或在新辅助化疗(CT)后接受手术切除(10%)。 37例患者(71.15%)使用了各种CT方案,但无显着疗效。 5年和10年OS率分别为59%和41%。肿瘤大小是我们系列中唯一出现的预后因素。彻底的手术切除仍然是这种侵袭性化学耐药性肿瘤的最佳治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号